Company intelligence / Profile preview
Tasly Pharmaceutical Group Co., Ltd.
- Ownership
- Public · 600535
- Employees
- ~20000
- Development stage
- Phase 3
Overview
Tasly has achieved global regulatory approvals for over 500 products. Its lead botanical drug T89 (Dantonic) completed an FDA Phase III trial for chronic stable angina with demonstrated clinical benefits in blood circulation and energy metabolism. Other programs are at various stages from preclinical to Phase III.[5][4][6]
- Therapeutic areas
- OncologyPulmonologyCardiovascularInfectious Diseases
- Modalities
- Herbal medicines (modernized Chinese medicine)Small moleculesPolypeptides/biologicsStem cells[6][3][5]
- Industry
- Pharma
Drug pipeline
66 assets65 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $3.2B
- Total revenue
- $1.2B
- Enterprise value
- $2.7B
Beyond the preview
Go deeper on Tasly Pharmaceutical Group Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tasly Pharmaceutical Group Co., Ltd..